中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

28 records (took 0.026 seconds)

    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE
    11.
    发明申请
    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开

    公开(公告)号：US20190154706A1

    公开(公告)日：2019-05-23

    申请号：US16257770

    申请日：2019-01-25

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hans-Peter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68 ,  G01N33/62 ,  A61K31/40

    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION
    12.
    发明申请
    TnT BASED DIAGNOSIS OF PAROXYSMAL ATRIAL FIBRILLATION 有权

    公开(公告)号：US20230062697A1

    公开(公告)日：2023-03-02

    申请号：US17821951

    申请日：2022-08-24

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68 ,  G01N33/74

    Abstract: The present invention relates to a method for diagnosing a recent paroxysmal atrial fibrillation. The method is based on the determination of the at least one marker selected from the group consisting of a cardiac Troponin, NT-proBNP (N-terminal prohormone of brain natriuretic peptide), hsCRP, IL-6 (Interleukin-6) and IGFBP7 (Insulin like growth factor binding protein 7) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). Further, the present invention relates to a method for identifying a subject being treatable with anticoagulation therapy. Further envisaged are systems, reagents and kits used in performing the methods disclosed herein.

    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE
    16.
    发明申请
    MARKER FOR STATIN TREATMENT STRATIFICATION IN HEART FAILURE 审中-公开
    心脏失败症状治疗的标记标记

    公开(公告)号：US20160169911A1

    公开(公告)日：2016-06-16

    申请号：US15054255

    申请日：2016-02-26

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Hanspeter Brunner ,  Thomas Dieterle ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg ,  Andre Ziegler

    IPC: G01N33/68 ,  G01N33/62

    CPC classification number: G01N33/6893 ,  A61K31/40 ,  G01N33/62 ,  G01N33/6869 ,  G01N33/6872 ,  G01N2333/47 ,  G01N2333/475 ,  G01N2333/495 ,  G01N2333/5412 ,  G01N2800/325 ,  G01N2800/52

    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

    Abstract translation: 本发明涉及鉴定患有心力衰竭的患者可能对包含他汀类药物的疗法有反应的方法。 该方法基于测量选自GDF-15（生长分化因子15），尿素，SHBG（性激素结合球蛋白），尿酸，PLGF（胎盘生长因子），IL-6（ 白细胞介素-6），转铁蛋白，心肌肌钙蛋白，sFlt-1（可溶性fms样酪氨酸激酶-1），前白蛋白，铁蛋白，骨桥蛋白，sST2（可溶性ST2）和hsCRP（高灵敏度C反应蛋白） 从病人。 进一步设想的是预测患者遭受死亡或住院的风险的方法，其中所述患者具有心力衰竭并经历包含他汀类药物的治疗。 该方法还基于至少一种上述标记的水平的测量。

    BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE
    17.
    发明申请
    BIOMARKERS IN THE SELECTION OF THERAPY OF HEART FAILURE 审中-公开
    生物标志物选择心脏失败的治疗方法

    公开(公告)号：US20150268251A1

    公开(公告)日：2015-09-24

    申请号：US14730615

    申请日：2015-06-04

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Christian Zaugg ,  Dirk Block ,  Ursula-Henrike Wienhues-Thelen ,  Hans-Peter Brunner ,  Friedemann Krause ,  Fabian Model ,  Vincent Rolny

    IPC: G01N33/68

    CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8139 ,  G01N2800/325 ,  G01N2800/52 ,  G01N2800/60

    Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

    Abstract translation: 本发明涉及一种用于鉴定有资格给予选自β-阻滞剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统抑制剂的至少一种药物的受试者的方法。 该方法基于选自GDF-15（生长分化因子15），内皮抑素，mimecan，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。 来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，P1NP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。 此外，该方法包括将所确定的量与参考量进行比较的步骤。 本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。 本发明还涉及用于鉴定合适的给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。

    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING
    18.
    发明申请
    IDENTIFICATION OF PATIENTS WITH ABNORMAL FRACTIONAL SHORTENING 有权

    公开(公告)号：US20220412991A1

    公开(公告)日：2022-12-29

    申请号：US17891458

    申请日：2022-08-19

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

    Assessing whether a subject shall be subjected to imaging based diagnostic
    19.
    发明授权
    Assessing whether a subject shall be subjected to imaging based diagnostic 有权

    公开(公告)号：US11454634B2

    公开(公告)日：2022-09-27

    申请号：US15911699

    申请日：2018-03-05

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Dirk Block ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Christian Zaugg

    IPC: G01N33/68 ,  A61B5/055 ,  A61B8/08

    Abstract: The present invention relates to a method for assessing whether a subject shall be subjected to an imaging based diagnostic assessment. The method is based on the determination of the amount(s) of a cardiac Troponin and/or Fibroblast Growth Factor 23 (FGF-23) in a sample from the subject, and on the comparison of the, thus, determined amount(s) with a reference amount (reference amounts). The present invention also relates to a system for performing an assessment whether a subject shall be subjected to an imaging based diagnostic assessment and to reagents and kits used in performing the methods disclosed herein. Moreover, the present invention is directed to a method for predicting the risk of mortality and/or of a cardiovascular event. Also encompassed is a method for diagnosing an early stage of LVH in a subject having a preserved left ventricular ejection.

Patent Agency Ranking